| Literature DB >> 26557863 |
Yuping Yan1, Mingzhe Wang2, Liang Zhang3, Zhenwei Qiu4, Wenfei Jiang2, Men Xu2, Weidong Pan2, Xiangjun Chen5.
Abstract
Objective. The objective is to observe whether the traditional Chinese medicine (TCM) Nao-Xue-Shu oral liquid improves aphasia of mixed stroke. Methods. A total of 102 patients with aphasia of mixed stroke were divided into two groups by a single blind random method. The patients treated by standard Western medicine plus Nao-Xue-Shu oral liquid (n = 58) were assigned to the treatment group while the remaining patients treated only by standard Western medicine (n = 58) constituted the control group. Changes in the Western Aphasia Battery (WAB), Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and hemorheology parameters were assessed to evaluate the effects of the treatments. Results. Excluding the patients who dropped out, 54 patients in the treatment group and 51 patients in the control group were used to evaluate the effects. Significant and persistent improvements in the WAB score, specifically comprehension, repetition, naming, and calculating, were found in the treatment group when the effects were evaluated at the end of week 2 and week 4, respectively, compared with baseline. The naming and writing scores were also improved at the end of week 4 in this group. The comprehension and reading scores were improved at the end of week 4 in the control group compared with the baseline, but the improvements were smaller than those in the treatment group. The percentages of patients at the 0-1 range of mRS were increased at the end of week 2 and week 4 in both groups, but the improvements in the treatment group were much larger than those in the control group. Greater improvements in the NIHSS scores and the hemorheology parameters in the treatment group were also observed compared with the control group at the end of week 2 and week 4. Conclusion. Nao-Xue-Shu oral liquid formulation improved aphasia in mixed stroke patients and thus might be a potentially effective drug for treating stroke aphasia.Entities:
Year: 2015 PMID: 26557863 PMCID: PMC4629027 DOI: 10.1155/2015/709568
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Background characteristics of the patients of mixed stroke with aphasia.
| Group |
| Gender | Age (y) | Educational level ( | Handedness ( | Aphasia type ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Primary | Middle | College or more | L | R | Motor | Receptive | Mixed | |||
| Treatment group | 54 | 38 | 16 | 63.32 ± 5.1 | 13 | 24 | 17 | 5 | 49 | 23 | 19 | 12 |
| Control group | 51 | 37 | 14 | 64.6 ± 4.9 | 11 | 23 | 17 | 4 | 47 | 21 | 17 | 13 |
Quantitative changes of Western aphasia battery (WAB) between before and after the additional treatments in the treatment and control groups.
| Comprehension | Repetition | Naming | Reading | Calculating | Writing | |
|---|---|---|---|---|---|---|
| Treatment group | ||||||
| Before | 0.68 ± 0.22 | 0.53 ± 0.17 | 0.46 ± 0.31 | 0.57 ± 0.26 | 0.43 ± 0.37 | 0.62 ± 0.25 |
| Week 2 | 0.76 ± 0.17 | 0.70 ± 0.32 | 0.52 ± 0.28 | 0.67 ± 0.25 | 0.56 ± 0.28 | 0.67 ± 0.21 |
| Week 4 | 0.87 ± 0.12 | 0.75 ± 0.21 | 0.62 ± 0.24 | 0.77 ± 0.18 | 0.67 ± 0.22 | 0.77 ± 0.12 |
| Control group | ||||||
| Before | 0.69 ± 0.23 | 0.54 ± 0.12 | 0.46 ± 0.25 | 0.56 ± 0.21 | 0.45 ± 0.29 | 0.63 ± 0.28 |
| Week 2 | 0.70 ± 0.21 | 0.60 ± 0.19 | 0.49 ± 0.21 | 0.58 ± 0.24 | 0.48 ± 0.27 | 0.65 ± 0.25 |
| Week 4 | 0.77 ± 0.19 | 0.63 ± 0.25 | 0.52 ± 0.17 | 0.65 ± 0.22 | 0.53 ± 0.33 | 0.68 ± 0.19 |
Note: p < 0.05 and p < 0.01 compared with before for the same group; # p < 0.05 compared with control group at the same time.
Figure 1Changes in the modified Rankin score (mRS) between before and after the additional treatments in the treatment and control groups. Note: p < 0.05 and p < 0.01 compared with before for the same group; ## p < 0.01 compared with control group at the same time.
Figure 2Changes in the National Institutes of Health Stroke Scale (NIHSS) scores between before and after the additional treatments in the treatment and control groups. Note: p < 0.05 and p < 0.01 compared with before for the same group; ## p < 0.01 compared with control group at the same duration.
Changes in hemorheology between before and after the additional treatments in the treatment and control groups.
| WBVLS (mPa·s) | WBVHS (mPa·s) | PV (mPa·s) | ESRE | Fibrinogen (g/L) | EA index | |
|---|---|---|---|---|---|---|
| Treatment group ( | ||||||
| Before | 18.83 ± 4.36 | 3.82 ± 0.57 | 1.81 ± 0.52 | 68.27 ± 39.25 | 4.82 ± 1.25 | 4.72 ± 0.81 |
| Week 2 | 17.96 ± 4.09 | 3.72 ± 0.35 | 1.68 ± 0.32 | 59.19 ± 41.62 | 4.19 ± 1.02 | 3.96 ± 0.63 |
| Week 4 | 16.65 ± 3.74 | 3.53 ± 0.32 | 1.47 ± 0.44 | 53.56 ± 40.69 | 3.47 ± 0.72 | 3.25 ± 0.52 |
| Control group ( | ||||||
| Before | 18.74 ± 5.05 | 3.82 ± 0.35 | 1.81 ± 0.37 | 67.82 ± 41.25 | 4.79 ± 1.46 | 4.70 ± 0.65 |
| Week 2 | 18.38 ± 5.23 | 3.79 ± 0.62 | 1.76 ± 0.42 | 64.99 ± 39.02 | 4.02 ± 1.33 | 4.65 ± 0.92 |
| Week 4 | 17.99 ± 4.59 | 3.77 ± 0.53 | 1.71 ± 0.38 | 63.47 ± 44.72 | 3.95 ± 1.49 | 3.97 ± 0.59 |
Note. WBVLS: whole blood viscosity low shear; WBVHS: whole blood viscosity high shear; PV: plasma viscosity; ESRE K value: erythrocyte sedimentation rate equation K value; and EA index: erythrocyte aggregation index. p < 0.05 and p < 0.01 compared with before for the same group; # p < 0.05 compared with control group at the same duration.